Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA: VMP vs MP in Untreated Multiple Myeloma
NCT00111319Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Time to Progression. Started Dec 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00111319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111319.